Lifeboat Foundation

Researchers at Western Sydney University in Australia have teamed up with tech giants Intel and Dell to build a massive supercomputer intended to simulate neural networks at the scale of the human brain.

They say the computer, dubbed DeepSouth, is capable of emulating networks of spiking neurons at a mind-melting 228 trillion synaptic operations per second, putting it on par with the estimated rate at which the human brain completes operations.

The project was announced at this week’s NeuroEng Workshop hosted by Western Sydney’s International Centre for Neuromorphic Systems (ICNS), a forum for luminaries in the field of computational neuroscience.

This brain implant can reverse paralysis.

---

His brain implant made headlines in 2016. Now, he’s fighting for everyone to afford one.

The first cellular map of a mammalian brain is here.

---

High-resolution atlas charts neural neighborhoods for more than 5,300 cell types.

A stroke happens when blood flow is lost to part of the brain. Your brain cells cannot get the oxygen and nutrients they need from blood, and they start to die in a few minutes. This can cause lasting brain damage, long-term disability, or even death.

---

A stroke can occur when an obstruction such as a blood clot travels from another part of the body and lodges inside an artery in the brain.

When an arterial wall becomes damaged, various types of emboli, or obstructions, can form. Emboli can be made up of various substances such as platelets, elements in the blood that help it clot, blood clots that form elsewhere and pass to the damaged area, cholesterol, or a combination of things.

Continue reading “Stroke — Health Video: MedlinePlus Medical Encyclopedia” »

Headquartered in Oxford, UK, MitoRx is working on orally delivered mitochondrial protective therapeutics targeting mitochondrial dysfunction linked to the progression of conditions such as Duchenne muscular dystrophy and Huntington’s disease, along with other neurodegenerative diseases. The company says the new funding will be allocated towards its preclinical work in Huntington’s disease, activating its first neurodegenerative disease program, and exploring research collaborations and partnerships.

MitoRx anticipates delivering preclinical results in Duchenne muscular dystrophy, Huntington’s disease, and COPD next year.

“Interim results in our Duchenne program demonstrate that our muscle-penetrative lead asset preserves strength in oxidative muscle, and confirms mitochondrial modulation,” said Dr Christine Charman, Chief Development Officer at MitoRx. “These results will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in Orlando during March 2024.”

A new study has illustrated how a protein called Snail helps brain cells coordinate in response to injury, showing that how much Snail is produced affects whether an injury heals efficiently.

A suite of improvements enables the NexGen 7T to image sub-microliter neuron clusters.

Worldwide, more than one billion people are obese. Obesity is a risk factor for cardiovascular disease, diabetes, and some cancers. But permanently losing weight isn’t easy: complex interactions between body systems such as gut physiology, hormones, and the brain are known to work against it. One method for weight loss is intermittent energy restriction (IER), where days of relative fasting alternate with days of eating normally.

“Here we show that an IER diet changes the human brain-gut-microbiome axis. The observed changes in the gut microbiome and in the activity in addition-related brain regions during and after weight loss are highly dynamic and coupled over time,” said last author Dr. Qiang Zeng, a researcher at the Health Management Institute of the PLA General Hospital in Beijing. The study has been published in Frontiers in Cellular and Infection Microbiology.

The authors used metagenomics on stool samples, blood measurements, and functional magnetic resonance imaging (fMRI) to study changes in the composition of the gut microbiome, physiological parameters and serum composition, and brain activity in 25 obese Chinese women and men on an IER diet. Participants were on average 27 years old, with a BMI between 28 and 45.

Progression independent of relapse activity (PIRA) has been increasingly recognized in people with multiple sclerosis (MS; NEJM JW Neurol May 24 2022 and JAMA Neurol 2022; 79:682). To learn more about PIRA, investigators used data from the Italian MS Register on 16,130 patients with relapsing-remitting MS, including 1,383 with pediatric-onset MS (POMS; median age at onset, 16), 14,113 with adult-onset MS (AOMS; median age at onset, 29), and 634 with late-onset MS (LOMS; median age at onset, 52).

Compared with patients with POMS, patients with LOMS had the highest incidence of PIRA (hazard ratio

---

, 2.98), followed by those with AOMS (HR, 1.42). Compared with the POMS patient group, the LOMS patient group had the lowest risk for relapse-associated worsening (HR, 0.69), followed by the AOMS group (HR, 0.88). Cumulative PIRA incidence was 1.3% of patients at age 20 years, increased rapidly between ages 21 and 30 (9%), and rose progressively from 40 to 70 (from 22% to 79%). Cumulative incidence of relapse-associated worsening showed a different pattern of increases over time (e.g., 0.5% at age 20; 7.8% at age 40; 14.4% at age 50; 24.1% at age 60; 27.7% at age 70).

These authors provide data supporting the notion that MS pathophysiology is different between patients with PIRA and those with relapse-associated worsening. While relapse-associated worsening seems to increase gradually and reach a plateau, PIRA begins in the 20s and continues to increase. PIRA encompasses accumulating neurodegenerative processes, supporting the concept that a subset of patients experience progression even within the relapsing-remitting phase of the disease.